GlassScriptPhysician profile
Mark Thomas Voellinger
NPI 1619170693
$45,235.91
in general payments reported to CMS, 2019-2025
36 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,001 · 2020: $1,611 · 2021: $2,015 · 2022: $4,388 · 2023: $11K · 2024: $11K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $7,741 · Gift: $243 · Travel and Lodging: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,100.00 |
| Food and Beverage | $7,740.67 |
| Gift | $243.31 |
| Travel and Lodging | $137.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34,620.58 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,400.22 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Braintree Laboratories, INC. | $999.30 | 2019-2024 | Sutab, Suflave |
| Pfizer INC. | $833.90 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $660.37 | 2019-2025 | Linzess |
| Genzyme Corporation | $630.96 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $611.07 | 2019-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $530.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $355.62 | 2021-2024 | Zeposia |
| Allergan, INC. | $294.80 | 2019-2020 | |
| Janssen Biotech, INC. | $267.40 | 2021-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $244.47 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $231.62 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $210.59 | 2019-2025 | Epclusa |
| Qol Medical, LLC | $209.38 | 2021-2024 | Sucraid, Sucraid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $144.85 | 2022 | |
| Abbott Laboratories | $142.21 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $123.16 | 2020-2022 | |
| Alfasigma USA, INC. | $79.67 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $69.51 | 2024-2025 | Idacio, Adalimumab-Aacf |
| Edwards Lifesciences Corporation | $69.49 | 2021 | |
| Ucb, INC. | $57.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $54.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $50.10 | 2019 | |
| Amgen INC. | $42.09 | 2023 | Amjevita, Avsola |
| Mallinckrodt Hospital Products INC. | $39.41 | 2024-2025 | Terlivaz |
| Csl Behring | $38.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.56 | 2022 | |
| Redhill Biopharma INC. | $33.91 | 2022 | |
| Daiichi Sankyo INC. | $32.85 | 2019 | |
| Shionogi INC | $28.92 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.94 | 2024 | Dupixent |
| Celltrion USA INC. | $21.54 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $16.59 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.28 | 2023 | Rebyota |
| Lilly USA, LLC | $13.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Voellinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.